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Abstract
Background: Few studies exist on hospital-based seroprevalence of  triple positivity of  HIV/HBV/HCV in Nigeria. 
Objectives: The study aimed at determining the triple positivity of  HIV, HBsAg and HCV among HIV-infected individuals 
in Abeokuta, Nigeria and defining the influence of  these triple infections on CD4+ counts of  HIV-infected individuals as 
antiretroviral therapy improves in Nigeria. 
Methods: Enumeration of  CD4+ levels in 183 HIV-infected persons was done with Partec Flow Cytometer. Seropositivity 
of  HBsAg and anti-HCV antibody was detected with rapid kits. 
Results: From the result obtained, significance variance (p<0.05) existed between HIV positive persons and persons who 
tested positive to HIV/HBV/HCV triple infection before and after the commencement of  HAART. Of  these infections, 
31(16.9%) had HBV/HCV/HIV triple infection, while 152(83.1%) had HIV mono infection only, 56(30.6%) had HBV/
HIV dual infection only and 43(23.5%) had HCV/HIV dual infection only. Significant variance (p<0.05) also existed be-
tween subjects with CD4 counts of  <200 cells/µl, 200-499 cells/µl and >500 cells/µl. Highest seroprevalence of  HIV 
(35.0%) was found in age groups 35-44 years and >65 years had the least (2.7%). Significant variance (p<0.05) also existed in 
the progression of  CD4+ lymphocytes cells between subjects with persistent decrease (32.3%) in CD4+ lymphocytes cells 
and those with fluctuation in their CD4+ lymphocytes cells (12.9%) after the commencement of  ART. 
Conclusion: The study further confirms that triple positivity of  HIV/HBV/HCV infection is common in Abeokuta, Nige-
ria. Testing of  these triple infections should be a big concern in the best choice and commencement of  ART. Also, the study 
showed that consistent and prolonged use of  HAART had a positive impact on the CD4 count of  HIV-infected individuals. 
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Introduction
Dual or triple infections with human immunodeficien-
cy virus (HIV), hepatitis B and C viruses (HBV and 
HCV) remain a major public health concerns as most 
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drugs have considerably enhanced the control and/or 
management of  single infections1. There is increasing 
evidence that triple infections of  HIV/HBV/HCV is 
a common unrestricted health issues2 which affects the 
clinical course of  the disease3-4. They are overwhelm-
ing disease agents that shared modes of  transmission5-7, 
thus HIV infected individuals are at risk of  dual or triple 
infections with HBV and HCV infections8. Long-last-
ing infections with HIV, HBV, and HCV are major pub-
lic health problems6 which may potentially be as a result 
of  virological interactions and could have an underlying 
immunological mechanism4,9-10.
Dual infections with HIV/HBV or HIV/HCV and 
triple infections with HIV/HBV/HCV is also vastly 
prevailing among intravenous drug users (IDUs)11-13. 
Amongst the transmissible blood-borne viruses through 
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the parenteral route (blood transfusion and sexual inter-
course), HIV, HBV and HCV are significant and have 
numerous consequences6,13-15. However, epidemiology 
of  HIV-HBV-HCV triple infections varies as a result of  
differences in background of  hepatitis infections and 
routes of  HIV transmission16. These viruses does not 
merely create asymptomatic tenacious infections with 
chance sequelae, nevertheless they similarly lead to ma-
jor illness and death when spread by transfusion6,17. 
Immunologically, the incursion of  the human body by 
any of  HIV, HBV or HCV is initially known to innate 
immunity, thereafter to the cellular and humoral im-
mune reaction7,18-22. Furthermore, cellular and humor-
al immunity consist of  cluster of  differentiation-4+ 
(CD4+) T-helper cells-1 and cytotoxic CD8+T-cells 
which mark and fix endogenously treated viral pro-
teins which are conveyed on the superficial of  diseased 
hepatocytes, and are ultimately disintegrate on the long 
run7,23-24. This facilitates shedding of  HIV, HBV and 
HCV from the body of  immunocompetent ill persons. 
This leads to immune-intermediated hepatocytes (liver) 
impairment7,25. The explicit cellular and humoral im-
mune reaction is consist of  antibodies targeted at par-
ticular antigens of  HIV, HBV and HCV7. The absence 
or presence of  anti-HCV antibodies or HBsAg is meas-
urable by particular laboratory investigations, besides, 
they consequently function as dependable markers of  
normal infection, which are valuable in epidemiology 
of  HIV, HBV and HCV7,26-29.
In the case of  CD4+, which is a glycoprotein conveyed 
on the exterior of  regulatory T cells, T-helper cells, den-
dritic cells, monocytes and macrophages and; they are 
the primary target for HIV30. The CD4+ T-lymphocytes 
cells however, are used to measure disease progression 
and to decide the commencement of  ART31. HIV leads 
to a consistent decrease in CD4+ T-lymphocytes cells. 
Majority of  people with HIV have been observed to 
have fallen in the CD4+ T-lymphocytes cells over time. 
Persons with AIDS show T-cell lymphopenia, a forfei-
ture of  CD4+ lymphocytes and comparative prolifera-
tion in CD8+subtype and in the CD3+CD4-CD8- sub-
type31. A clear-cut count of  CD4+T cells is essential 
for dependable and well-ordered antiretroviral therapy 
(ART) and monitoring31. Therefore, the CD4+lympho-
cytes count is useful to monitor the immune system, 
when to start HIV treatment and effectiveness of  HIV 
treatment32. 
Highly active antiretroviral therapy (HAART) has dis-
torted HIV and AIDS from a consistently deadly ail-
ment into a controllable long-lasting infection and has 
been presented to reinstate CD4+ cells in HIV positive 
persons8,33,34. The achievements of  HAART might be 
conceded by dual or triple infections with hepatitis vi-
ruses as they are recognized to have antagonistic con-
sequences on the scenario of  HIV and hepatitis infec-
tions8,34,35. Subsequently, improved attention has to be 
paid on dual or triple infections of  hepatitis viruses and 
HIV particularly in the emerging countries such as Ni-
geria where these sets of  viruses are prevalent8.
While the proportion of  individuals with dual or triple 
positivity is lesser, the blend of  HIV and HBV and/or 
HCV is a precarious co-existence6,36-38 and might devise 
a damaging consequence on the infected persons and 
the outcome of  treatment6]. Dual or triple infections 
with HBV or HCV upsurges the menace for hepato-
toxicity of  HAART and possibility of  inception of  an 
AIDS-defining illness, likened with infection with HIV 
only8,34,35,39. Studies previously have proposed that dual 
positivity of  HIV/HBV or HIV/HCV and triple posi-
tivity HIV/HBV/HCV have dampened immune reac-
tion to HAART likened with those with only HIV40-42. 
While others studies have reported some degrees of  
immune reinstatement in individuals with HIV/HBV 
or HIV/HCV dual-infection42-48. Management of  either 
hepatitis virus is multifaceted because of  pharmacoki-
netic interfaces with constituents of  HAART regimens. 
Hence, the marvel of  HIV and hepatitis viruses’ dual or 
triple infections is a cause for concern8.
Although the HIV dual or triple infections with HBV 
and/or HCV has been documented globally in persons 
prone to blood-borne diseases, restricted data are ob-
tainable on the degree of  dual or triple infection and 
consequence of  these viruses on the immune system 
in emerging countries8]. Nigeria fits to the set of  coun-
tries vastly prevalent for viral hepatitis49. Limited studies 
have been completed on HIV, HBV, HCV individually 
in Nigeria nevertheless the information about the in-
terrelationship between these viruses and their conse-
quence on the immune system remains vague8.
Thus, the study aimed at determining the triple posi-
tivity of  HIV/HBV/HCV in HIV-infected persons in 
Abeokuta, Nigeria. The study also aimed at defining 
the impact of  these infections on CD4+ counts among 
HIV-infected persons as antiretroviral therapy improves 
in Nigeria.
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Methodology
Study area and population
The present study was carried out at the Federal Med-
ical Centre, Idi-Aba, Abeokuta, Ogun State, Nigeria. 
One hundred and eighty three (183) HIV-positive per-
sons participated in the study, one hundred were fe-
males while 83 were males. Participants were confirmed 
HIV-positives, ages 15 years and above. Approval was 
obtained from the Ethics Committee of  the hospital. 
Participants also gave their consents and pertinent con-
fidentiality was kept all through the study. 
Sample collection and preparation
Venous blood from the 183 HIV-infected persons were 
obtained into plain tubes without any anti-coagulants. 
Sera from the venous blood was obtained by spinning 
for 5 min at 2000 resolution per minutes (rpm). The de-
canted sera were kept at -20oC for serological analysis. 
In the same vein, another four millilitres (4ml) of  blood 
was collected into an EDTA anti-coagulated tube for 
enumeration of  CD4+ cells.
Serologic assay
The whole samples were retested using HIV rapid kits 
(Bioline Standard Diagnostic Inc, Korea). It is a quick 
immunochromatography technique for detecting IgA, 
IgG and IgM antibodies specific to HIV-1/2 concur-
rently in serum. A red colour line in the patient and 
control windows is indicative of  seropositivity while the 
existence of  the red-coloured line in the control and its 
non-appearance in the patient window is indicative of  
seronegativity. 
The samples were also screened for HBsAg and an-
ti-HCV antibody using ACON HBsAg and anti-HCV 
antibody test kits respectively. This is a membrane-based 
immunoassay (manufactured by ACON Lab., Inc. San 
Diego, USA). In this kit, the test region had been pre-
viously coated with recombinant HBsAg and HCV an-
tigen. Both kits are based on chromatographics vessel 
movement to form coloured lines. The existence of  
coloured line is indicative of  seropositivity while its 
non-appearance is indicative of  seronegativity. 
Assay for the CD4+ lymphocytes cells were carried out 
using the Partec Flow Cytometer (CyFlow counter). 
This is a fluorometric method used to differentiate and 
count cells present in the sample. Cells in suppression 
pass through in flow curvette in a narrow stream. Fi-
nally fluorescence signal are segmentally generated and 
signal are detected and displayed. The CD4 levels of  
each patient were examined at initial visit and then three 
months and six months after commencement of  ART 
treatment.
Data analysis
The proportions of  participants with triple infection 
of  HIV/HBV/HCV were calculated. CD4+ counts 
of  individuals infected with HIV/HBV/HCV were 
presented in figures with sex, age and the CD4+ count 
progression as well as their response to ART. Relevant 
chi-square statistics were calculated to complement 
each result using SPSS 20.0 window packages.
Results
In the present study, 183 HIV-infected individuals were 
examined (Table 1). Of  which, 100 (54.6%) were fe-
males and 83 (45.4%) were males. 
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Table 1:  Sex and Age Distribution of HIV-Infected Subjects 
Risk factors Number (%)  
Sex   
Males 83 (45.4) 
Females 100 (54.6) 







Total 183 (100.0) 
  
Higher percentages of  HIV positives were in age group 
35-54 years (35.0%) while age group 65-74 years (2.7%) 
had the least as shown in Table 1. Significant difference 
(p<0.05) existed between sex, age and seropositivity of  
HIV. 
Of  these 183 HIV-infected subjects, 152(83.1%) had 
HIV mono infection only, 56(30.6%) HBV/HIV dual 
infection only and 43(23.5%) had HCV/HIV dual in-
fection only and 31 (16.9%) had HBV/HCV/HIV tri-
ple infection. Figure 1 shows the sex-related seropreva-
lence of  triple infections of  HIV/HBV/HCV. 
The sex-related seropositivity revealed higher seroposi-
tivity of  HIV/HBV/HCV in males (54.8%)] compared 
to females (45.2%). However, no significant variance 
(p>0.05) existed between sex and triple infections of  
HIV/HBV/HCV.
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Figure 1:  Sex- related seroprevalence of HIV/HBV/HCV triple infections 
 
Figure 2: Age-related seroprevalence of HIV/HBV/HCV triple infections  
Figure 3 shows CD4+ lymphocytes cells of  HIV-infect-
ed subjects before and after initiation of  ART. It showed 
that CD4+ lymphocytes cells at the initial visit before 
commencement of  the antiretroviral therapy (ART) 
with <200 cells/µl were 73 (39.9%) and subjects having 
CD4+ lymphocytes cells >500 cells/µl were 46(25.1%). 
The age-related seroprevalence of  HIV/HBV/HCV is 
shown in Figure 2. Triple seropositivity of  HIV/HBV/
HCV (38.7%) was higher in age group 35-44 years than 
in others. However, no significant variance (p>0.05) ex-
isted between age and triple infections of  HIV/HBV/
HCV.
 
Figure 3: CD4 Count of HIV-Infected subjects before and after Initiation of ART 
CD4+ lymphocytes cells after 3 months of  initial visit 
to the ART clinic showed that there was a marginal de-
crease among individual with CD4+ lymphocytes cells 
[72(39.9%)] and marginal increase with those CD4+ 
lymphocytes cells between 200-499 cells/µl [65(35.5%] 
and individual with CD4+ lymphocytes cells of  >500 
cells/µl were same as the initial visit [46(25.1%)]. 
Furthermore, CD4+ lymphocytes cells after 6 months 
of  initial visit to the ART clinic showed that there was 
a marginal decrease in subjects with CD4+ lympho-
cytes cells <200 cells/µl [70(38.3%)] and subjects hav-
ing CD4+ lymphocytes cells of  200-499 cells/µl were 
62(33.3%). Subjects with CD4+ lymphocytes cells of  
>500 cells/µl increased to 52(28.4%) showing a posi-
tive impact on the CD4+ lymphocytes cells on the basis 
of  consistent rise in the use of  ART (Figure 3). 
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Figure 4: CD4 Count Progression in relation to seroprevalence of HIV/HBV/HCV  
triple infections  
This difference is also statistically associated (P<0.05).
Figure 4 shows CD4+ lymphocytes cells progressions 
in relation to HIV-HBV-HCV triple infections among 
the subjects. It showed a progression of  CD4+ lympho-
cytes cells among subjects with HIV-HBV-HCV triple 
infections [17 (55.8%)]. Significant difference (p<0.05) 
existed between CD4+ lymphocytes cells progressions 
of  HIV-infected subjects and HIV/HBV/HCV triple 
infections (Figure 4).
Discussion 
Several studies have proposed that human immuno-
deficiency virus can fast-track the usual sequence of  
long-lasting HCV and/or HBV13. Earlier studies devise 
that persons with long-lasting HCV/HBV and HIV will 
experience swift advancement besides being prone to 
death in comparison with non-HIV infected persons13. 
Contrariwise, the consequence of  HCV and/or HBV 
on HIV infection remains indistinct13,38,50-51. Dual or tri-
ple infections of  HIV and hepatitis viruses have con-
siderably amplified disease and death rates of  HIV and 
AIDS infected-persons13,38,50-51. 
Triple infections are thus rising menace in Nigeria and 
cautious attention is needed due to its adversarial con-
sequences on HIV treatment reaction8. Thus, it became 
necessary to estimate the seroprevalence of  triple infec-
tions with HIV/HBV/HCV, particularly amid groups 
known to be a high-risk populace of  dual or triple in-
fections. The present study aimed at determining the 
seroprevalence of  HIV/HBV/HCV triple infections 
among HIV-infected individuals in Abeokuta, Nigeria. 
The study also aimed at defining the impact of  these in-
fections on CD4+ lymphocytes cells among HIV posi-
tive persons as access to antiretroviral therapy advances 
across the Nigerian nation. 
Of  the 183 HIV-infected subjects used in this study, 
152(83.1%) had HIV mono infection and 31 (16.9%) 
had HIV/HBV/HCV triple infections. Previous stud-
ies in Nigeria had reported varying seroprevalences of  
HIV/HBV/HCV infections. Forbi et al.8 had report-
ed an overall HIV/HBV/HCV prevalence of  7.2%. A 
3.9% seroprevalence of  HIV/HBV/HCV was report-
ed by Balogun et al.52 and 6.5% seroprevalence was re-
ported by Okeke et al.53. 
Higher seroprevalence of  HIV/HBV/HCV triple in-
fections in males than their female colleagues. Higher 
seroprevalence was recorded among age groups 35-44 
years than in other age groups. This is in consonance 
with what was reported previously in the Northern Ni-
geria16,54 and elsewhere in the world32,55-56. This may be 
due to fact that males at age group are most sexually 
active. Elsewhere, the triple infection rates of  19.1% 
and 10.4% was reported in China and Myanmar respec-
tively13. A seroprevalence of  1.83% was reported by 
Agarwal et al.57. Musyoki et al.58 reported 29.4% prev-
alence of  HIV/HBV/HCV infections in South Africa. 
Moreover, it has been indicated that the dual infections 
of  HIV/HBV and HIV/HCV) or triple infections of  
HIV/HBV/HCV is most common, though the dual or 
triple infections rates varies liable to risk groups, type 
of  exposure involved and geographic regions13,59-61. 
The usual antiquity of  HBV is identified to be intricated 
by HIV dual infections nevertheless the influence of  
HBV on the aftermath of  persons infected with HIV-1 
is contentious8,63. There was flawless clue of  amplified 
HCV infection in HIV positive persons in Nigeria. It 
is also well-known that HIV/HCV dual positivity fast-
track patients rapidly to AIDS defining clinical event, 
end-stage liver disease and death8,39,63. Unfortunately at 
this time, only HBV vaccine is available, HIV vaccine is 
under way and no active vaccine against HCV8.
The CD4+ lymphocytes values of  183 confirmed HIV 
positive persons were counted by means of  a superior 
fluorescence activated cell sorter system. The result in-
dicates that most of  the subjects were diagnosed when 
the CD4+ lymphocytes cells were <200 cells/ml. The 
CD4+ lymphocytes cells of  HIV/HBV/HCV triple in-
fected subjects were significantly lower (P<0.05) than 
those with HIV mono infection only. The details for 
the drop in CD4+ level is unclear however, it is rec-
ognised that there is disparity in outlying blood T-lym-
phocyte subsets and commotion in cellular immunity in 
the persons with long-lasting hepatitis B64. Also, HIV-
HBV-HCV triple infected individuals responded poorly 
to the ART treatment than those with HIV mono in-
fection only. This finding is in agreement with previous 
reports16,32,65-67.  
This study also showed a progression of  CD4+ lym-
phocytes cells among subjects with HIV-HBV-HCV tri-
ple infections [17(55.8%)]. The consistency and regular 
use of  antiretroviral therapy as prescribed by the coun-
selors improved the immunity of  the HIV infected indi-
vidual as indicated by progressive increase in the CD4+ 
lymphocytes cells which is in support with previous 
reports3,9,30,32,68-70. Forbi et al.8 in a similar study, report-
ed that rise in CD4+ cells after HAART does not alter 
in persons with triple infections of  HIV/HBV/HCV 
however, HCV seems to deter virological response to 
ART. 
Conclusion 
As far as we know, there are few reports on the triple 
positivity of  HIV/HBV/HCV infections in the highly 
HIV infected populations in Nigeria. This study further 
endorses the possibility and endemicity of  HBV and 
HCV dual or triple infections and increased infection in 
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HIV-infected individuals. Planned prevention, screen-
ing and treatment are needed to reduce further trans-
mission and morbidity of  these infections. Intensified 
HBV vaccination program is also advocated in Nigeria 
which is known to be able to substantially diminish the 
occurrence of  HBV infections. 
This study has also demonstrated that dual or triple 
infections of  HIV and hepatitis viruses (HBV and/or 
HCV) are on the rise in Nigeria. It seems to decline 
the CD4+ lymphocytes cells of  patients who have tri-
ple positivity of  HIV, HBV, and HCV. It also showed 
that consistent and prolong use of  antiretroviral thera-
py will influence positively CD4+ lymphocytes cells of  
HIV-infected individuals. Thus, we call for sustainable 
educational promotion programmes on the means of  
acquisition and spread of  HIV, HBV and HCV, as well 
as increasing HBV vaccinations in order to curtail the 
spread of  HIV, HBV and HCV in Abeokuta, Nigeria. 
However, further studies on the mechanism by which 
the HBV and HCV act as a cofactor for the HIV-in-
fected individual is thus warranted in this part of  the 
country.
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